Oncolytics Biotech(R) Inc. Announces 2009 First Quart...( CALGARY May 5 / Oncolytics Biotech In...)

CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three-month period ended March 31, 2009.

"The first quarter of 2009 was highlighted by the announcement of very positive results in several of our combination REOLYSIN(R) clinical trials," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to report clinical benefit in the majority of patients treated with REOLYSIN in combination with chemotherapy or radiation, paving the way for our pivotal program to begin this year."

    Selected First Quarter Highlights:

    -  Announced positive interim results from a U.K. Phase I/II combination
       REOLYSIN and paclitaxel/carboplatin trial for patients with advanced
       head and neck cancers. Of 12 evaluable patients, five patients had
       partial responses (PR) and four patients had stable disease (SD), for
       a clinical benefit rate (complete response + partial response + stable
       disease) of 75%;

    -  Announced positive results from a U.K. combination REOLYSIN and
       docetaxel trial for patients with a variety of advanced cancers.
       Fifteen of the 17 evaluable patients experienced SD or better,
       including two PR, three minor responses and 10 SD, giving a clinical
       benefit rate of 88%;

    -  Completed enrolment in a U.K. combination REOLYSIN and gemcitabine
       clinical trial. Of the ten patients evaluable for response, two
       patients (breast and nasopharyngeal) had PRs and five patients had SD,
       for a clinical benefit rate of 70%;

    -  Started patient enrolment in a U.S. Phase 2 Combination REOLYSIN and
       paclitaxel/carboplatin clinical trial for patients with non-small cell
       lung cancer with K-RAS or EGFR-activated tumo
'/>"/>
SOURCE  Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 
Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
2. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
3. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
4. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
5. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
6. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
7. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
9. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
10. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
11. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent